Screening for Brain Metastases in Patients With NSCLC: A Qualitative Study on the Psychologic Impact of Being Diagnosed With Asymptomatic Brain Metastases

Schoenmaekers, Janna; Bruinsma, Jeroen; Wolfs, Claire; Barberio, Lidia; Brouns, A.; Dingemans, Anne Marie C.; Hendriks, Lizza

doi:10.1016/j.jtocrr.2022.100401

Cited by 1 publication

(1 citation statement)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Early detection and control of BM can mitigate the increased healthcare costs, economic burden, and decreased quality of life (QoL) that come with a BM diagnosis. 91 Monthly healthcare costs have been shown to increase 4-fold from $5983 to $22 645 after BM diagnosis in NSCLC patients. 92 Furthermore, healthcare utilization also increased, with a 3-fold increase in outpatient visits and 6-fold increase in hospitalizations.…”

Section: Discussionmentioning

confidence: 99%

Brain metastasis screening in the molecular age

Tabor

Onoichenco

Narayan

et al. 2023

Neuro-Oncology Advances

View full text Add to dashboard Cite

The incidence of brain metastases (BM) amongst cancer patients has been increasing due to improvements in therapeutic options and an increase in overall survival. Molecular characterization of tumors has provided insights into the biology and oncogenic drivers of BM and molecular subtype-based screening. Though there are currently some screening and surveillance guidelines for BM, they remain limited. In this comprehensive review, we review and present epidemiological data on BM, their molecular characterization, and current screening guidelines. The molecular subtypes with the highest BM incidence are EGFR-mutated NSCLC, BRCA1, TN, and HER2+ breast cancers, and BRAF-mutated melanoma. Furthermore, BMs are more likely to present asymptomatically at diagnosis in oncogene-addicted NSCLC and BRAF-mutated melanoma. European screening standards recommend more frequent screening for oncogene-addicted NSCLC patients, and clinical trials are investigating screening for BM in HR+, HER2+, and TN breast cancers. However, more work is needed to determine optimal screening guidelines for other primary cancer molecular subtypes. With the advent of personalized medicine, molecular characterization of tumors has revolutionized the landscape of cancer treatment and prognostication. Incorporating molecular characterization into BM screening guidelines may allow physicians to better identify patients at high risk for BM development and improve patient outcomes.

show abstract

Section: Discussionmentioning

confidence: 99%